INSIGHTS ON FACILITY DESIGN

FACILITY DESIGN SOLUTIONS

  • Ibex™ Dedicate

    As the biopharma industry identifies faster and more efficient ways to deliver drugs to patients, such as break-through and fast track designations for accelerated approval, these progresses create pressure on both large and small drug manufacturers. As development timelines shorten, decisions related to drug commercialization need to be taken earlier, when key results are not yet available. And deciding on the scale and type of facility to build without complete data can create substantial risks with costly consequences.

  • GE Life Sciences Overview - Cell Processing

    Helping your cell therapies succeed through our reach and resources.

  • Genderless AseptiQuik® L Series Connectors

    Genderless AseptiQuik® Large Format 3/4", 1" and 1½" sanitary Connectors enable quick and easy sterile connections, even in non-sterile environments. The easy-to-use genderless design simplifies system integration and minimizes the risk of operator error. The connector's robust construction provides enhanced user confidence and reliable performance without the need for clamps, fixtures or tube welders. Biopharmaceutical manufacturers benefit from a full range of interchangeable 3/4" to 1½" flow solutions for production environments with the quality and market availability they expect from the leader in single-use connection technology.

  • Genderless AseptiQuik® L Series Connectors Datasheet

    Genderless AseptiQuik® L Connectors enable quick and easy sterile connections, in large-volume, high-flow production environments. The largeformat, 3/4" and 1" genderless design simplifies system integration and minimizes the risk of operator error.

  • Transformations In Biomanufacturing

    In biomanufacturing the only certainty is risk and the only constant is change. Technology is pushing new frontiers, new markets are opening up across the globe, and new competition is creating new levels of urgency—all under the ever more watchful eye of regulators.